Gilead

News

Gilead NASH drug fails late stage trial

Gilead's top late-stage drug selonsertib, for patients with compensated cirrhosis due to nonalcoholic steatohepatitis (NASH), has failed a phase 3 trial.

News

Pharma companies clear the R&D decks in Q4

The fourth-quarter results season has already seen a host of unwanted projects cleared from pharma companies' pipelines as they tighten their focus on the projects with the most chance of a

News

Gilead hires Roche's pharma chief Daniel O'Day as CEO

Roche executive Daniel O’Day is to take the helm at Gilead after John Milligan steps down as CEO at the end of this year, the company has announced.

News

NICE gives final seal of approval for Gilead's CAR-T in NHL

NICE has finalised its guidance recommending interim NHS funding for Gilead’s Yescarta CAR-T therapy, to treat patients with aggressive forms of non-Hodgkin lymphoma.

News

Gilead pushes on with NASH drug after phase 2 success

Gilead Sciences presented promising data on its research into advanced fibrosis caused by non-alcoholic steatohepatitis (NASH), one of several big pharma companies developing drugs for the

News

Novartis wants to blaze a trail in breast cancer with PI3K d...

Novartis is preparing to file its PI3K drug combination for a certain group of breast cancer patients, after late stage trial results showed its alpelisib combination stopped the disease pr

Gilead NASH drug fails late stage trial

Pharma companies clear the R&D decks in Q4

Gilead hires Roche's pharma chief Daniel O'Day as CEO

NICE gives final seal of approval for Gilead's CAR-T in NHL

Gilead pushes on with NASH drug after phase 2 success

Novartis wants to blaze a trail in breast cancer with PI3K d...

Delivering the right behavioural ingredients for the moment,...

How to meet your physicians where they are online

Gilead

Editor's Picks